← Back to Screener
Acumen Pharmaceuticals, Inc. Common Stock (ABOS)
Price$2.51
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)50.74%
Price vs S&P 500 (4W)4.27%
VGM Score67.80
Market Capitalization$187.79M
All Metrics
Book Value / Share (Quarterly)$1.21
P/TBV (Annual)0.73x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.46
Price vs S&P 500 (YTD)12.29%
Net Profit Margin (TTM)-509.72%
EPS (TTM)$-1.86
10-Day Avg Trading Volume0.35M
EPS Excl Extra (TTM)$-1.86
EPS (Annual)$-1.70
ROI (Annual)-48.29%
Cash / Share (Quarterly)$1.78
ROA (Last FY)-42.68%
EBITD / Share (TTM)$-1.87
ROE (5Y Avg)-32.47%
Operating Margin (TTM)-550.00%
Cash Flow / Share (Annual)$-1.91
P/B Ratio2.15x
P/B Ratio (Quarterly)1.95x
Net Income / Employee (Annual)$-1,700,000
ROA (TTM)-79.41%
EPS Incl Extra (Annual)$-1.70
Current Ratio (Annual)4.07x
Quick Ratio (Quarterly)4.42x
3-Month Avg Trading Volume0.71M
52-Week Price Return147.62%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.84
P/S Ratio (Annual)130.41x
Asset Turnover (Annual)0.03x
52-Week High$3.60
EPS Excl Extra (Annual)$-1.70
26-Week Price Return66.67%
Quick Ratio (Annual)3.92x
13-Week Price Return-8.13%
Total Debt / Equity (Annual)0.44x
Current Ratio (Quarterly)4.55x
Enterprise Value$167.04M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-509.03%
Cash / Share (Annual)$1.93
3-Month Return Std Dev69.16%
Net Income / Employee (TTM)$-1,887,900
ROE (Last FY)-56.10%
EPS Basic Excl Extra (Annual)$-1.70
Total Debt / Equity (Quarterly)0.35x
EPS Incl Extra (TTM)$-1.86
ROI (TTM)-92.30%
P/S Ratio (TTM)130.41x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.60
Price vs S&P 500 (52W)119.41%
Year-to-Date Return23.22%
5-Day Price Return3.59%
EPS Normalized (Annual)$-1.70
ROA (5Y Avg)-28.31%
Net Profit Margin (Annual)-509.03%
Month-to-Date Return8.79%
Cash Flow / Share (TTM)$-1.10
EBITD / Share (Annual)$-1.90
Operating Margin (Annual)-549.31%
LT Debt / Equity (Annual)0.32x
ROI (5Y Avg)-30.50%
LT Debt / Equity (Quarterly)0.19x
EPS Basic Excl Extra (TTM)$-1.86
P/TBV (Quarterly)0.49x
P/B Ratio (Annual)1.81x
Pretax Margin (TTM)-509.72%
Book Value / Share (Annual)$1.16
Price vs S&P 500 (13W)-17.87%
Beta0.34x
Revenue / Share (TTM)$0.00
ROE (TTM)-123.07%
52-Week Low$1.00
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.33est. -0.41
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.42
4.42
4.42
4.42
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ABOSAcumen Pharmaceuticals, Inc. Common Stock | — | — | B | $2.51 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing ACU193, a monoclonal antibody designed to treat Alzheimer's disease by targeting amyloid-beta oligomers. The company's therapeutic approach seeks to address what management identifies as a key underlying cause of neurodegeneration.